| Filed On | Filing |
|---|---|
| 28 Oct 2025 |
8-K: Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
SECTION 1. Registered Office. The registered office of Tourmaline Bio, Inc. (the “Corporation”) shall be established and maintained at the office of Corporation Service Company, in the City of Wilmington, in the County of New Castle, in ... |
| 12 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 09 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland; |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing – |
| 09 Jun 2025 |
8-K: Regulation FD Disclosure
Disclaimer 2 The material in this presentation regarding Tourmaline Bio, Inc. (“we,” “us” or the “Company”) is for informational purposes only and is intended for investor audiences. This presentation contains forward-looking statements ... |
| 06 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2025, Tourmaline Bio, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). A total of 25,684,479 shares of common stock were entitled to vote as of April 15, 2025, the record date for the A... |
| 20 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease |
| 02 May 2025 |
8-K: Results of Operations and Financial Condition
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – |
| 13 Mar 2025 |
8-K: Results of Operations and Financial Condition
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – |
| 10 Dec 2024 |
8-K: Regulation FD Disclosure
The material in this presentation regarding Tourmaline Bio, Inc. (“we,” “us” or the “Company”) is for informational purposes only. This presentation contains forward-looking statements within the meaning of the Private Securities Litigat... |
| 10 Dec 2024 |
8-K: Regulation FD Disclosure; Other Events
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – |
| 10 Oct 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 4, 2024, Dr. Yung Chyung gave notice of his decision to resign from his position as Chief Medical Officer of Tourmaline Bio, Inc. (the “Company”) in order to pursue another opportunity. His resignation will be effective on Oct... |
| 11 Sep 2024 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the... |
| 05 Sep 2024 |
8-K: Regulation FD Disclosure
The material in this presentation regarding Tourmaline Bio, Inc. (“we,” “us” or the “Company”) is for informational purposes only. This presentation contains forward-looking statements within the meaning of the Private Securities Litigat... |
| 08 Aug 2024 |
8-K: Results of Operations and Financial Condition
– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – |
| 27 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 25, 2024, the Board of Directors of Tourmaline Bio, Inc. (the “Company”) appointed Ryan Robinson to serve as the Company’s Chief Financial Officer and Treasurer, effective as of June 25, 2024 (the “Effective Date”). This position... |
| 07 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 5, 2024, Tourmaline Bio, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). A total of 25,646,509 shares of common stock were entitled to vote as of April 10, 2024, the record date for the A... |
| 13 May 2024 |
8-K: Results of Operations and Financial Condition
– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – |
| 19 Mar 2024 |
8-K: Results of Operations and Financial Condition
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – |
Loading...